flâneur

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma | Nature Medicine

nature.com · 1,932 words · saved by 1 readers

Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk melanoma results in higher response rates than nivolumab monotherapy and warrants future optimization of dosing regimens to preserve efficacy while limiting toxicity.

Data availability The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary Information. Whole-exome sequencing, T cell receptor sequencing and Nanostring digital spatial profiling data are available from the European Genome-phenome Archive under accession number EGAS00001003178. Change history 25 October 2018 In the version of this article originally published, there was an error in Fig. 1. In the neoadjuvant phase column, the n values for arms A and B were both reported to be 20. The n values for arms A and B were…

saved by

related reading